3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
4
Thoracic
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Breast
1
Conditions
Glioblastoma
108
Brain Neoplasms
106
Glioma
83
Neuroblastoma
34
Astrocytoma
26
Neoplasms
25
Medulloblastoma
25
Central Nervous System Neoplasms
25
Neurofibromatosis 1
23
Meningioma
23
Ependymoma
22
Sarcoma
21
Breast Neoplasms
18
Rhabdoid Tumor
16
Melanoma
16
Neurofibroma, Plexiform
15
Carcinoma, Non-Small-Cell Lung
15
Osteosarcoma
14
Wilms Tumor
13
Rhabdomyosarcoma
13
Thyroid Neoplasms
12
Sarcoma, Ewing
12
Hepatoblastoma
12
Gliosarcoma
12
Recurrence
11
Diffuse Intrinsic Pontine Glioma
11
Pheochromocytoma
10
Pancreatic Neoplasms
10
Neoplasm Metastasis
10
Ovarian Neoplasms
9
Interventions
belzutifan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
von Hippel-Lindau Disease
×
CNS
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA